© John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Edited By: Thomas A. Luger and Ralf Paus
Impact Factor: 3.578
ISI Journal Citation Reports © Ranking: 2012: 6/59 (Dermatology)
Online ISSN: 1600-0625
Instructions to authors
Presubmission inquiries should be sent to:
Thomas A. Luger
Department of Dermatology
University Hospital Münster
D-48149 Münster, Germany
Manchester, UK and Münster, Germany
Institute of Inflammation and Repair
University of Manchester
Manchester M13 9PT, UK
Production Editor: firstname.lastname@example.org
Effective with the 2013 volume, Experimental Dermatology will be published in an online-only format. No printed edition will be published. Your article will therefore appear online-only. All normal author benefits and services remain in place e.g. authors will continue to be able to order print reprints of articles if required.
Print subscription and single issue sales are available from Wiley’s Print-on-Demand Partner. To order online click here http://www.sheridan.com/LPM/Wiley
OnlineOpen is available to authors of primary research articles who wish to make their article available to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made available to non-subscribers upon publication via Wiley Online Library, as well as deposited in the funding agency's preferred archive. For the full list of terms and conditions, see http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms. Any authors wishing to send their paper OnlineOpen will be required to complete the payment form available from here. Prior to acceptance there is no requirement to inform an Editorial Office that you intend to publish your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in the same way as any other article. They go through the journal's standard peer-review process and will be accepted or rejected based on their own merit.
NEW: Online production tracking is now available for your article through Wiley-Blackwell’s Author Services.
Author Services enables authors to track their article - once it has been accepted - through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production so they don’t need to contact the production editor to check on progress. Visit http://authorservices.wiley.com/bauthor/ for more details on online production tracking and for a wealth of resources including FAQs and tips on article preparation, submission and more.
Regular research articles should not exceed 4000 words, not including tables, figures and references.
If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the WileyAuthor Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.
For authors signing the copyright transfer agreement
If the OnlineOpen option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below:CTA Terms and Conditions http://authorservices.wiley.com/bauthor/faqs_copyright.asp
For authors choosing OnlineOpenIf the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):
Creative Commons Attribution License OAA
Creative Commons Attribution Non-Commercial License OAA
Creative Commons Attribution Non-Commercial -NoDerivs License OAA
To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services at the below webpage:
If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK requirements.
For more information on this policy and the Journal’s compliant self-archiving policy please visit: http://www.wiley.com/go/funderstatement.
Additionally. authors are themselves responsible for obtaining permission to reproduce copyright material from other sources.
Manuscripts describing studies involving animals should comply with local/national guidelines governing the use of experimental animals and contain a statement indicating that the procedures have been approved by the appropriate regulatory body. Manuscripts concerned with human studies must contain statements indicating that informed, written consent has been obtained, that studies have been performed according to the Declaration of Helsinki and that the procedures have been approved by a local ethics committee. If individuals might be identified from a publication (e.g. from images) authors must obtain explicit consent from the individual.
Prior to submission, authors should carefully check the Ethical guidelines document available here.
Manuscript Submission. Experimental Dermatology is only accepting manuscripts electronically via an online submission site,
ScholarOne Manuscripts (formerly known as Manuscript Central). The use of an online submission and peer review site will speed the time to decisions, enable immediate distribution and allow authors to track their own manuscripts. To access this system for submission and review, go directly to http://mc.manuscriptcentral.com/exd .
Experimental Dermatology employs a plagiarism detection system. By submitting your manuscript to this journal you accept that your manuscript may be screened for plagiarism against previously published works.
Manuscripts should be submitted online at http://mc.manuscriptcentral.com/exd . Full instructions and support are available on the site and a user ID and password can be obtained on the first visit. Support can be contacted by phone ( 1 434 817 2040 ext. 167) Monday-Friday, or at http://mcv3support.custhelp.com.
Conflicts of Interest
When submitting a manuscript, authors are responsible for disclosing all financial and personal relationships that could be viewed as presenting a potential conflict of interest. To prevent ambiguity, all authors must state explicitly whether potential conflicts do or do not exist. This information should be included in the paper after the Acknowledgements section. In the event where there are no conflicts of interest to declare, authors must still include a statement in the paper to say so.
Whenever possible, authors are strongly encouraged to emphasize the clinical relevance of their work. In original papers, at least the final paragraph of the paper should include a discussion of the potential clinical relevance of the presented findings, whenever this makes sense.
Research Articles may not exceed 4000 words, not including tables, figures & references. They should contain a maximum of 4 display items in single column width (including figures and tables). Clinical studies are explicitly welcome, if they also contain major experimental research components. Please list the word count and number of display items on the cover page of the manuscript. Manuscripts exceeding these limits will be returned to Authors without review. Each manuscript component should begin on a new page in the following sequence: title page; abstract; key words (3 to 5); introduction; methods; results; discussion; acknowledgments; references; tables (each table, complete with title and footnotes, on a separate page); legends for illustrations. Number pages consecutively, beginning with the title page. Type the page number in the upper right-hand corner of each page. Number the tables consecutively with arabic numerals. For any further details, consult the 'Uniform requirements for manuscripts submitted to bio-medical journals'', Ref. (2) below.
Methods in Experimental Dermatology
Methods manuscripts may not exceed approx 2,500 words (not including references) and should contain a maximum of 3 display items. In addition, Experimental Dermatology regularly publishes Methodological Reviews that provide state-of-the-art, authoritative coverage of important laboratory techniques across all areas of investigative dermatology and molecular biomedicine. These critical reviews also cover typical problems and limitations encountered with the discussed method, suggest problem solving approaches, and offer pragmatic advice from experienced laboratory practitioners not only for newcomers but also readers interested in the field. The submission of Methods Reviews, is invited by the Editors. If you are interested in writing a Methods Review, please contact the Editors.
Speculative, thought-provoking Viewpoint essays (max. 2500 words, 100 refs.) and standard review articles (max. 4000 words, 200 refs.) are invited by the editors or associate editors. These always welcome specific suggestions for topics and prospective authors, ideally along with submission of a brief structural outline. Instructions for the design of Viewpoints essays and Review articles are available from the editorial office and details are negotiated with the editors.
Patterns of Expression
Patterns of Expression is a category of paper reporting the comprehensive pattern of expression of a new or important gene during embryonic development and/or in the adult organism, highlighting interesting or unexpected findings. Patterns of Expression papers should contain data using multiple complimentary approaches, including but not limited to, in situ hybridization, immunohistochemistry, immunofluorescence, real-time PCR, western and northern blot. Papers should not exceed 2,500 words and do not require an invitation by the Editor. Documentation should be stringently restricted to what is really essential in order to convincingly document the reported expression pattern. Non-essential, Supporting Information, also in color, may be displayed free-of-charge on the journal website.
Letter to the Editor, Methods Letters to the Editor
Letters and Methods Letters to the Editors in Experimental Dermatology represent full-fledged short reports, and a corresponding abstract is presented via PubMed (letter format: 1000 words: structured into BACKGOUND, QUESTIONS ADDRESSED, EXP. DESIGN, RESULTS, CONCLUSIONS abstract 150 words; maximum 2 small figures or tables and 30 references). Our letter format also allows for generous online Supporting Information (including more extensive information on materials and methods, more figures/tables and additional references). Please note that LETTERS and METHODS LETTERS TO THE EDITORS should not exceed 3 printed pages. Additional pages must be paid for at a rate of GBP 170 per page. As a special service to authors and readers, in contrast to full original articles, LETTERS and METHODS LETTERS TO THE EDITORS in Exp Dermatol are now made freely available to all readers so as to render them maximally accessible (OpenAccess policy).
Commentary: My favorite historical paper
This new publication category features short commentaries that call attention to a seminal historical paper (i.e. original article, review, letter, or book chapter), which currently is not widely known or cited any longer and which the author feels strongly should be brought back to the attention of a wide range of readers and disciplines. Title: needs to attract attention of both experts and non-cognoscenti; must indicate the relevant field of skin research, and should encapsulate at least a first hint at why this paper is important. Text: 600-1000 words, up to 20 references, 1 figure or table and unlimited e-supplement. The commentary should argue succinctly why the author feels that the selected historical paper is fascinating; has made a major contribution to its field of research and/or is very important for other reasons of general interest. Please elaborate also how this paper has provided major novel concepts or very important pointers that remain pertinent today and are relevant for future research in this area. An extremely condensed summary of this is to be presented in a separate abstract (max. 100 words). Ideally, the author should obtain permission from the relevant publisher to reprint the entire historical article in the e-supplement of the commentary so that the full historical paper becomes easily and generally accessible.
HYPOTHESIS LETTERS offer a forum for the proposal of novel hypotheses on important skin research topics of general interest. These hypotheses must be developed on the basis of the published literature, must be stated clearly and succinctly, and must be experimentally testable. Hypotheses manuscripts that, if confirmed, are likely to lead to important changes in dermatological therapy and/or pathobiology concepts are favored. Hypothesis Letters have a maximum of 800 words, 1 composite figure, and 50 references, and can be complemented by an extensive e-supplement (with additional figs., text, and refs.), and are to be structured as follows: Background, Premises, Hypothesis, How to test the hypothesis, Relevance and perspectives. The corresponding short abstract (150 words) is to be structured into "Background", "Hypothesis", "Relevance".Letter: Mouse Mutants with Absent/Minimal Skin Phenotype
This new publication category features genetic mouse manipulations in the skin (e.g. transgenic gene over/misexpression or gene targeted ablation) that manifest a minimal or no detectable phenotype. Typically a considerable amount of funding resources, research time and effort by students/postdocs has been invested to generate the necessary preliminary data before abandoning a genetic mouse manipulation on project that yields no or only a minimal phenotype. In addition, several labs may embark on similar genetic mouse manipulation efforts with "negative" results, multiplying the loss of money/time resources if the results are not reported. This new letter category will serve as a platform to share such findings by reporting high-quality data that document successful gene manipulation at the RNA/protein level with several complementary methods, such as in situ hybridization, immunofluorescence/histochemistry, genotyping and real-time PCR of isolated cells, and an in-depth "absence of phenotye" analysis of skin tissues at relevant time points (including rigorous quantifications) using tissue stains and cell-type specific gene marker analysis. Letters should be less than 1000 words with a maximum of 2 figures and 30 references. Additional figures, materials, and methods are allowed in a generous "Supporting Information" section.Commentary from the Editorial Board
Commentaries on recent articles published in the journal; 500-1000 words, max 25 references, 1-2 figures or tables; commentary authors are welcome to invite co-authors of their choice; non-editorial board members are welcome to contact current board members in order to team up with them to write a commentary.
Supporting Information – Video/Podcast
Authors are invited to submit a short video/Podcast (up to 7 minutes). The content should include an overview about the publication and the novelty of it. The videos/Podcasts are produced by the authors and are subject to the editor’s approval before publication. The editor may request revisions if necessary. For further information on recommended file types and requirements for submission, please visit: http://authorservices.wiley.com/bauthor/suppinfo.asp
Illustrations. All figures should clarify the text and their number should be kept to a minimum. Details must be large enough to retain their
clarity after reduction. Illustrations should preferably fill single column width (81 mm) after reduction, although in exceptional cases 2/3 width (120 mm) or full page width (168 mm) will be accepted. Line drawings should be professionally drafted and photographed; halftones should exhibit high contrast. A linear size scale should be incorporated into electron microscopic pictures. Colour illustrations will be accepted free of charge.
Abbreviations and Symbols. Use only standard abbreviations. All units will be metric. Use no roman numerals in the text. In decimals, a decimal point, and not a comma, will be used. Consult the CBE style manual: a guide for authors, editors and publishers in the biological sciences, 4th edition, Arlington, Virginia, 1978. Avoid abbreviations in the title. The full term for which an abbreviation stands should precede its first use in the text unless it is a standard unit of measurement. Units of measurement should be expressed in accordance with the SI and CIE recommendations (see Ref. 3, below).
References. Number references consecutively in the order in which they appear first in the text. Identify references in text, tables and
legends by Arabic numerals (in parentheses). All references cited, and only these, must be listed at the end of the paper. Journal titles
should be abbreviated according to the style used in Index Medicus. The names of unlisted journals should be spelled out.
1. Standard journal article
(For more than 3 authors, list the first three, then et al.) Parrish J A, Fitzpatrick T B, Tanebaum L et al. Photochemotherapy with oral methoxsalen and long wave ultraviolet light. N Engl J Med 1974: 291: 1207–1222.
2. Corporate author
International Steering Committee. Uniform requirements for manuscripts submitted to biomedical journals. Ann Intern Med 1997; 126: 36–47.
3. Agency publication
International lightning vocabulary, Paris: Bureau Central de la Commission International de l’Éclairage, 1970; vol. 3. Armstrong Lowe. A guide to international recommendations on names and symbols for quantities and on units of measurement. Geneva: WHO, 1975 (Progress in Standardization, No. 2).
4. Chapter in a book
Frain-Bell W. The photodermatoses. In: Rook A, ed. Recent advances in dermatology. Edinburgh: Churchill Livingstone, 1973: 101–133.
English-language editing: Authors for whom English is a second language may choose to have their manuscript professionally edited before submission or during the review process. For further information go to: http://authorservices.wiley.com/bauthor/english_language.asp
Proofs. The corresponding author will receive an email alert containing a link to a web site. A working e-mail address must therefore be provided for the corresponding author. The proof can be downloaded as a PDF (portable document format) file from this site. Acrobat Reader will be required in order to read this file. This software can be downloaded (free of charge) from the following web site:
This will enable the file to be opened, read on screen and printed out in order for any corrections to be added. Further instructions will be sent with the proof. Hard copy proofs will be posted if no e-mail address is available. Excessive changes made by the author in the proofs, excluding typesetting errors, will be charged separately.
Offprints. Free access to the final PDF offprint of your article will be available via author services only. Please therefore sign up for author services if you would like to access your article PDF offprint and enjoy the many other benefits the service offers’
Author material archive policy. Please note that unless specifically requested, Wiley will dispose of all hardcopy or electronic material submitted 2 months after publication. If you require the return of any material submitted, please inform the editorial office or production editor as soon as possible if you have not yet done so.
Note to NIH Grantees. Pursuant to NIH mandate, Wiley will post the accepted version of contributions authored by NIH grant-holders to PubMed Central upon acceptance. This accepted version will be made publicly available 12 months after publication. For further information, see www.wiley.com/go/nihmandate.
The journal is a member of and subscribes to the principles of the Committee on Publication Ethics.
Disclaimer. The Publisher and Editors cannot be held responsible for errors or any consequences arising from the use of information
contained in this journal; the views and opinions expressed do not necessarily reflect those of the Publisher and Editors, neither does the publication of advertisements constitute any endorsement by the Publisher and Editors of the products advertised.